Sienna Biopharmaceuticals, Inc.

17 articles about Sienna Biopharmaceuticals, Inc.

• Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice

  11/14/2019

  Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, on November 12, 2019, the Nasdaq Hearings Panel (the “Panel”) granted the Company’s request for continued listing on the Nasdaq Stock Market (“Nasdaq”),

• Sienna Biopharmaceuticals Announces Court Approval of Chapter 11 Bidding Procedures Bids due on December 2, 2019 by 5:00 p.m. Eastern Time

  11/14/2019

  Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that, on November 13, 2019, the United States Bankruptcy Court for the District of Delaware entered an order approving Sienna’s proposed bidding procedures and Chapter 11 sale process timeline.

• 

  Sienna Biopharmaceuticals Files for Bankruptcy, Delaying Phase III Psoriasis Trial

  9/18/2019

  The dermatological drug maker will use Chapter 11 protection to restructure the company, including a possible sale of assets, and will delay development of its Phase III-ready psoriasis treatment.

• Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125

  2/14/2018

  The trial will evaluate the safety, tolerability and efficacy of SNA-125 compared to vehicle and other reference formulations in approximately 15 patients with chronic psoriasis.

• Sienna Biopharmaceuticals Establishes Corporate Advisory Board

  12/12/2017

  The Corporate Advisory Board comprises accomplished and highly regarded medical opinion leaders within dermatology and aesthetics.

• Sienna Biopharmaceuticals Reports Third Quarter 2017 Financial Results

  11/9/2017

  Total operating expenses for the three months ended Sept. 30, 2017, were approximately $14.3 million.

• Sienna Biopharmaceuticals Announces First Patient Dosed in Phase IIb Trial of Topical SNA-120

  10/24/2017

  The trial has 190 patients with at least moderate pruritus and mild-to-moderate psoriasis.

• Sienna Biopharmaceuticals Reports Second Quarter 2017 Financial Results

  9/7/2017

• Sienna Biopharma Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares

  8/2/2017

• Sienna Biopharma Nabs $65 Million in IPO

  7/27/2017

• Sienna Biopharma Appoints Erle Mast, Former CFO And Co-Founder Of Clovis Oncology To Board Of Directors

  6/14/2017

• SoCal's Sienna Biopharma Bags $40 Million Series B Financing

  4/24/2017

• Richard Peterson Joins Sienna Biopharma As Chief Financial Officer

  3/24/2017

• Former Allergan Chief David Pyott Signs On As Special Advisor To Sienna Biopharma

  2/28/2017

• Sienna Biopharma Acquires Creabilis plc

  12/6/2016

• Sienna Biopharma Announces Second Closing Of Series A Financing

  7/13/2016

• Sienna Biopharma Launches with $34 Million and a Roster Full of Former Kythera Execs

  5/2/2016